Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$29.7MCash on Hand
53mo Cash Runway
Follow ENSC by emailGet an email when ENSC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ENSC, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Reported Q3 2026 results with $29.7 million in cash and equivalents as of September 30, 2026. Completed the Cy Biopharma acquisition, adding CY200 for CRPS, and recorded a non-cash IPR&D charge of about $79.9 million. Net loss attributable to common stockholders was $82.3 million. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 4, 2026 ·
Leadership Director Will Chang intends to resign after the December 14, 2026 annual meeting. CEO Dr. Lynn Kirkpatrick will become Chief Operating Officer after the meeting, and President James Morrisson will become CEO. Form 8-K · SEC filing
Oct 23, 2026 ·
Financing Ensysce Biosciences filed a preliminary resale prospectus covering up to 433,907,000 shares of common stock issuable on conversion of Series C preferred stock, tied to an August 5, 2026 merger with Cy Biopharma, a private placement, side letters, and two related agreements. Form S-3 · SEC filing
Oct 16, 2026 ·
Files audited Cy Biopharma financials for 2025 and 2024, unaudited statements for the first half of 2026 and 2025, and pro forma combined statements for the Cy Biopharma acquisition closed August 5, 2026. Form 8-K/A · SEC filing · Press release
Sep 29, 2026 ·
Shareholder vote Ensysce amended the certificate of designation for its Series C Non-Voting Convertible Preferred Stock on September 25, 2026, removing Section 6.5.3, which had provided a holder cash redemption right tied to failure to deliver common stock on conversion. Form 8-K · SEC filing
Aug 25, 2026 ·
Listing Nasdaq said Ensysce now meets the $2.5 million stockholders' equity requirement but will be delisted if it does not show compliance in its next periodic report. Form 8-K · SEC filing
Aug 24, 2026 ·
Financing Ensysce closed the first tranche of a Series C Preferred financing on August 7, 2026, raising more than $21 million in gross proceeds of a planned approximately $43 million. The second tranche awaits a clinical trial milestone. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1 · Recruiting · Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) Registry primary completion date, not a results date
Aug 2026 · Phase 3 · Recruiting · PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not ENSC's own candidates): Naltrexone Hydrochloride, Oxycodone Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ENSC holds $29.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.7M/quarter from operations,
an estimated runway of 53 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:15 · Low
Cash runway 53 months
Going-concern doubt in the latest 10-Q +15These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count 19,456,794 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ENSC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENSC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.